Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22412002 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BAAK1HTTPOLB | |
| SCHEMBL29711718 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BAAK1HTTPOLB | |
| SCHEMBL22411914 | 0.84 | GSTP1 (0.35) | AAK1GSTP1GSTM2ALDH1A1CYP3A4 | |
| SCHEMBL24496934 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BAAK1TACR1 | |
| SCHEMBL29711743 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BAAK1TACR1 | |
| SCHEMBL24496828 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BAAK1TACR1 | |
| SCHEMBL29711866 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BAAK1TACR1 | |
| SCHEMBL24496957 | 0.82 | ALDH1A1 (0.48) | HTTALDH1A1MAPTGAALMNA | |
| SCHEMBL28951034 | 0.82 | ALDH1A1 (0.48) | HTTALDH1A1MAPTGAALMNA | |
| SCHEMBL28951011 | 0.82 | ALDH1A1 (0.48) | HTTALDH1A1MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-114591351-B | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2022117090-A1 | POLYCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都科岭源医药技术有限公司 | 2022-06-09 | — | — | WO | disclosed |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| CN-114591351-A | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3938369-A1 | TYK2 INHIBITORS AND USES THEREOF | Esker Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113811534-A | TYK2 inhibitors and uses thereof | 埃斯克疗法股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276977-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MTNR1A 1126/4885MTNR1B 879/4885AAK1 92/4885 |
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | MTNR1A 1126/4885MTNR1B 879/4885AAK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.